eXoZymes (EXOZ)
NASDAQ:EXOZ
Want to see EXOZ full AI Analyst Report?
Top Page
eXoZymes
(NASDAQ:EXOZ)
Select Model
Select Model
Rating:47Neutral
Price Target:
$10.00
▼(-12.97% Downside)
Action:Reiterated
Date:05/15/26
The score is primarily held down by weak financial performance (no revenue, widening losses, and significant ongoing cash burn with a shrinking equity base). Technicals are mixed and not signaling strong momentum, while valuation is difficult to support due to negative earnings and no dividend. Corporate events suggest progress toward raising capital, but also increase dilution risk.
Positive Factors
Capital access
Active engagement with underwriters and a prepared investor presentation signal formal steps to access public capital. Over the medium term this can materially extend runway, fund R&D and development milestones, and reduce immediate liquidity strain if executed successfully.
Negative Factors
Pre-revenue, widening losses
The company has no product revenue and materially larger operating losses over recent years. Persistent negative earnings drain equity and limit reinvestment capacity, creating a structural need for external funding until commercialization or licensing yields sustainable revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Capital access
Active engagement with underwriters and a prepared investor presentation signal formal steps to access public capital. Over the medium term this can materially extend runway, fund R&D and development milestones, and reduce immediate liquidity strain if executed successfully.
Read all positive factors
eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)2.40K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue GrowthN/A
EPS Growth-32.48%
CountryUS
Employees31
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.15
Shares Outstanding8,478,992
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap10.00T>
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.54K
Enterprise Value/Ebitda-8.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
eXoZymes Business Overview & Revenue Model
Company Description
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform al...
How the Company Makes Money
null...
eXoZymes Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -267.38K | 0.00 | -147.75K | -59.41K |
| EBITDA | -9.43M | -5.59M | -1.60M | -1.18M | -1.15M |
| Net Income | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
Balance Sheet | |||||
| Total Assets | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Total Debt | 1.24M | 1.39M | 1.61M | 608.77K | 720.63K |
| Total Liabilities | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Stockholders Equity | 3.40M | 10.42M | -384.32K | 1.37M | 1.20M |
Cash Flow | |||||
| Free Cash Flow | -6.67M | -8.90M | -1.47M | -1.44M | -2.01M |
| Operating Cash Flow | -6.50M | -8.51M | -1.18M | -1.26M | -1.59M |
| Investing Cash Flow | -150.22K | -359.22K | -311.17K | -87.21K | -312.25K |
| Financing Cash Flow | -27.71K | 18.52M | 1.00M | 1.36M | 2.31M |
eXoZymes Risk Analysis
eXoZymes disclosed 46 risk factors in its most recent earnings report. eXoZymes reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Changes to United States tariff and import/export regulations may have an adverse effect on our business, financial condition and results of operations. Q1, 2026
2.
Government Action on tariffs and research grants and other funding may impede our ability to conduct our research and to raise capital by and for our partner companies and other clients. Q1, 2026
eXoZymes Peers Comparison
UnderperformOutperform
Sector (61)
EXOZ
eXoZymes
9.72
-4.18
-30.07%
BDRX
Biodexa Pharmaceuticals
3.36
-49.64
-93.66%
ADTX
Aditxt
0.16
-39,540.80
-100.00%
NCEL
NewcelX
3.54
-19.86
-84.87%
VRAX
Virax Biolabs Group Ltd. Class A
0.21
-0.75
-77.97%
eXoZymes Corporate Events
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Prepares Investor Presentation for Proposed Public Offering
Positive
May 7, 2026
On May 7, 2026, eXoZymes Inc., a Nevada corporation, circulated an investor presentation to potential underwriters, offering participants, and prospective investors. The materials were prepared in connection with a proposed public offering of the ...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Advances Toward Planned Securities Offering Preparation
Positive
Apr 10, 2026
On April 10, 2026, eXoZymes Inc., a Nevada corporation, prepared an investor presentation as part of its efforts to support a proposed securities offering. The presentation was circulated to potential underwriters and other participants in the con...
Business Operations and StrategyRegulatory Filings and Compliance
eXoZymes Updates Investor Presentation for NCTx Business
Neutral
Mar 31, 2026
On March 30, 2026, eXoZymes Inc. issued an updated investor presentation for its NCTx business, signaling a refreshed communication of its strategy and operations to the market. The release underscores the company’s effort to provide current...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.